Peru has secured enough COVID-19 vaccine to give nearly three-quarters of its population at least one dose when the immunization is available, as reported in NASDAQ.
The country reached agreements with Pfizer and the global vaccine distribution program COVAX for the provision of 23.1 million doses. Some vaccine regimes will require two doses.
The government said it had signed a binding agreement with Pfizer for the purchase of 9.9 million doses of its vaccine which is in testing.
An additional 13.2 million doses will be bought through COVAX, which is headed by the GAVI, the Vaccine Alliance, and the World Health Organization, and aimed at promoting equitable access.
Peru's health ministry added that it was negotiating with other vaccine developers, including Sinopharm and Sinovac Biotech, Moderna, Novovax, Johnson & Johnson, AstraZeneca and COVAXX, a unit of United Biomedical, as well as Russia's Gamaleya Institute, which developed the coronavirus vaccine candidate Sputnik V.